Michael Madsen is a Judge Advocate in the US Army.  His current full-time job is an Attorney for the Air Force and he's a JAG in the Army Reserves.

After graduating law school and completing a JD/MBA program, Michael worked in the private sector before joining the Army at the age of 33.  He wanted to serve his country and found that the Army gave him the best opportunity, even though he had several injuries, mostly from playing football in college at Brigham Young University.  

I've always admired Michael b/c he gave up lucrative opportunities in the world of law to join the military.  He stands by his grandfather's wise counsel: "It doesn't matter where you serve; it matters how you serve."  

Madsen comes from a line of American Patriots.  His grandfather is Ezra Taft Benson, who was the Secretary of Agriculture under President Eisenhower, and was the 13th President of The Church of Jesus Christ of Latter-day Saints.  

In early 2020, Michael was diagnosed with Acute Lymphoblastic Leukemia.  We discuss in great detail how this affected his family (his wife and 4 young kids), and how he's doing today with the multitude of side effects from this disease, treatments and his bone marrow transplant (thanks to his sister).  In addition, how his faith, the faith of his family and those around him, continue to strengthen him and his family.

Also mentioned in this episode:

Jupiter Patch Boards

Copyright 2024 Thad Forester
http://www.patriottothecore.com
email questions to thad@patriottothecore.com

Ep 118 | Michael Madsen - Army Judge Advocate (JAG) | Acute Lymphoblastic Leukemia Survivor

BUFFALO, NY- July 2, 2024 – A new editorial paper was published in Oncotarget's Volume 15 on June 20, 2024, entitled, “Genomics has more to reveal.”

In this new editorial, researchers Laurène Fenwarth and Nicolas Duployez from the University of Lille and CHU Lille discuss molecular and cytogenetic analyses that are now used to identify mutations and structural variants defining distinct subtypes of acute myeloid leukemias (AML) and myelodysplastic syndromes (MDS). These genetic considerations have become essential for risk stratification and the selection of appropriate treatments, including the use of allogeneic hematopoietic stem cell transplantation. 

“Despite over 15 years of genomic research since the first publication of the AML genome and large studies like The Cancer Genome Atlas (TCGA) [2], around 15% of AML cases remained genetically unclassifiable with current knowledge.”

Notably, several studies in both adults and children identified a subset of AML without known initiating events but particularly enriched in FLT3- ITD and WT1 mutations, and normal karyotypes with an overall unfavorable prognosis. In 2021–2022, notably thanks to advancements in bioinformatic approaches and tools, recurrent somatic tandem duplications (TD) of a portion of the UBTF gene were identified in high-risk pediatric AML cases. 

“With increased screenings of retrospective cohorts, the characteristics associated with this molecular alteration have since been confirmed. UBTF-TD are considered initiating events in leukemogenesis and define a distinct entity of myeloid malignancies.”

DOI -  https://doi.org/10.18632/oncotarget.28596

Correspondence to - Nicolas Duployez - nicolas.duployez@chu-lille.fr

Video short - https://www.youtube.com/watch?v=WVY_ejhr7Fc

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28596

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, acute myeloid leukemia, genomics, UBTF

About Oncotarget 

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Oncotarget

Editorial: Genomics Has More to Reveal

BUFFALO, NY- July 19, 2024 – A new #editorial paper was #published in Oncotarget's Volume 15 on July 2, 2024, entitled, “DDX41 and its unique contribution to myeloid leukemogenesis.”

In this new editorial, researcher Hirotaka Matsui from the National Cancer Center Hospital in Tokyo, Japan, and Kumamoto University discusses myeloid neoplasms. Until the early 2000s, myeloid neoplasms attributable to genetic backgrounds were considered exceedingly rare, with notable exceptions limited to those arising as components of systemic syndromes such as Fanconi anemia and Li-Fraumeni syndrome. Historically, no hematopoietic-specific tumor syndromes had been identified until 1999, when RUNX1 was implicated as the causative gene for familial platelet disorder with a predisposition to acute myeloid leukemia (AML). 

Subsequently, in 2004, CEBPA was recognized as another critical gene responsible for inherited AML. The subsequent advent and widespread application of comprehensive genetic analysis facilitated the identification of germline pathogenic variants in genes such as ANKRD26, ETV6, and GATA2 among patients with myeloid neoplasms that developed against a background of inherited thrombocytopenia or systemic disorders. It is now established that genetic predisposition is present in approximately 10% of myeloid neoplasms, underscoring the fact that myeloid neoplasms with a genetic background are by no means exceptional.

“Among these, myeloid neoplasms caused by DDX41 variants are particularly noteworthy due to their distinct disease phenotype and pathogenesis [2].”

DOI -  https://doi.org/10.18632/oncotarget.28603

Correspondence to - Hirotaka Matsui - hmatsui@ncc.go.jp

Video short - https://www.youtube.com/watch?v=AQXIdS1amhM

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28603

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, acute myeloid leukemia, DDX41, myelodysplastic neoplasms, myeloid neoplasms with germline predisposition, R-loop

About Oncotarget 

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh

MEDIA@IMPACTJOURNALS.COM

DDX41’s Unique Contribution to Myeloid Leukemogenesis

New York Times bestselling author and journalist Suleika Jaouad began writing her Emmy Award-winning column, “Life, Interrupted,” from her hospital room, chronicling her experiences as a young adult with cancer. She joins to discuss her remarkable life, career, and bestselling memoir, Between Two Kingdoms.

Best of Design Matters: Suleika Jaouad

MIKE IS BACK and CANCER FREE! After a 2 year hiatus from the show while diagnosing and defeating Stage 4 Lymphoblastic Lymphoma Leukemia Cancer by pushing his body to the extreme, he sits down with his good friend Tony and discusses the entire journey and what crazy limits he put himself through to beat such an aggressive and deadly cancer so fast. You don't want to miss this episode and the details could very well spark the path to many peoples future successes, while fighting cancer of their own. 

The two also talk about free-diving and living on the island they call paradise, Phuket.

Be sure to hit that subscribe button and click the bell for notifications so you can watch all of our Podcasts, Headlines, and Recaps as soon as they are released!

This Podcast is filmed on location and brought to you by AKA Thailand, The Worlds Premier Luxury Training Resort FOR ANYONE! Book online now at: https://akathailand.com AND AKA Thailand is now EVERYWHERE with its new online educational and entertainment platform! Get the app in the Apple and Google Play stores or go to AKAThailand.TV to watch hundreds of HD Muay Thai Techniques, Tips, Advice, Whole Fight Card Live Streams From Local Thai Stadiums, HD Fights, Replays, Community, Bootcamps and more soon! 

Our official Real Quick with Mike Swick Podcast Shirts and AKA Thailand merch is now available online at https://www.akathailand.com/store 

Check out all the clips and highlights of The Real Quick With Mike Swick Podcast at the official clip account, Quick Swick Clips:
http://www.youtube.com/c/QuickSwickClips


Timestamps:
0:00 Welcome to the show

Business E-mail: Media@AKAThailand.com

Follow:

Mike Swick:
http://www.Instagram.com/Mike_Swick
http://www.twitter.com/OfficialSwick
http://www.Facebook.com/MikeSwick

Mike Swick is a 15-time UFC veteran and a former top contender in two weight divisions. He is also the Founder and CEO of the AKA Thailand super gym resort in Phuket Thailand, as well as the owner of Swick Savage™ and Savage Life Media™.  

Follow Us: 
http://www.youtube.com/c/RealQuickwMikeSwickPodcast
http://itunes.apple.com/us/podcast/real-quick-w-mike-swick-podcast/id1268441670
http://soundcloud.com/RealQuickPodcast 
http://Instagram.com/RealQuickWithMikeSwick 
http://Twitter.com/RQMSPodcast
​​https://www.stitcher.com/s?fid=408915&refid=stpr

Host: Mike Swick
Co-Host: Tony Myshlyaev (@Tones.Of.Blue - Instagram)
Produced & Directed by: Mike Swick 
Filmed & Edited by: James Speers
Clips and Marketing by: Evan Shoman
Music Producer: Benny Youngbaht
Music: Danny Bunnathong
Artwork: Simon Netherton

For more info about AKA Thailand:
http://AKAThailand.com
https://www.youtube.com/c/AKAThailandGym
http://Instagram.com/AKAThailand
http://Facebook.com/AKAThailandGym
http://Twitter.com/AKAThailand

Thank you for watching!

#cancer #cancerfree #cancersurvivor #cancersmasher #mikeswick #akathailand #realquickwithmikeswickpodcast #realquickwithmikeswick
#podcast #podcasts #podcasting #podcastclips #lymphoma #leukemia

How I Beat Stage 4 Leukemia Cancer In 1 Year - EP 147 My Strategy And Journey

In this Healthful Woman Podcast episode, Dr. Nathan Fox speaks with listener Jodi about her daughter, Annie. They discuss Annie's glowing personality, her leukemia diagnosis at 17 years old, her subsequent cancer fight, and sadly, her passing away last year. They also discuss the Annietober 365 Foundation, which was created in Annie's memory.

"Annietober365 and the Gift of Life" - with Jodi Eisner

Bad! (ft. CR33PER)

Today we are bringing you a conversation on treatment with Bruton tyrosine kinase inhibitors for patients with treatment-naïve chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).

Ryan Haumschild, PharmD, MS, MBA, CPEL, vice president of ambulatory pharmacy at Emory Healthcare and Winship Cancer Institute, spoke with 3 experts: Tara Graff, DO, medical oncologist, Mission Cancer and Blood; Jacqueline Barrientos, MD, MS, chief, Hematologic Malignancies, and director, Oncology Research at Mount Sinai Comprehensive Cancer Center; and Matthew Davids, MD, MMSc, director of Clinical Research, Division of Lymphoma, Dana-Farber Cancer Institute, and associate professor of medicine, Harvard Medical School.

They covered a wide range of topics including the data on treatment regimens for both CLL and MCL, the cost of treatment, patient-specific considerations during treatment decision making, and the future of treatment.


Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL

In early 2022, Jon Batiste stands at the pinnacle of his career, earning eleven GRAMMY® nominations, including Album of the Year. While composing American Symphony, an ambitious orchestral work that reimagines classical traditions through a diverse musical lens, Batiste is hit with life-altering news: his partner, author Suleika Jaouad, faces a recurrence of her long-dormant cancer. Academy Award-nominated director Matthew Heineman captures their intertwined journeys in the GRAMMY®-nominated American Symphony, a deeply intimate exploration of art, love, and survival in the face of uncertainty. For the full article go to BLRBMag.com.

American Symphony - A BLRBMag Review

BUFFALO, NY - March 31, 2025 – A new #research paper was #published in Oncotarget, Volume 16, on March 21, 2025, titled “FGR Src family kinase causes signaling and phenotypic shift mimicking retinoic acid-induced differentiation of leukemic cells."

A research team led by first author Noor Kazim and corresponding author Andrew Yen from Cornell University discovered that the FGR protein—traditionally considered a cancer-promoting molecule—can instead trigger leukemia cells to mature.  This effect mirrors the response usually induced by retinoic acid (RA); a compound derived from vitamin A that is widely used in cancer therapy. Their finding presents a potential new path for therapies targeting acute myeloid leukemia (AML) and related cancers.

Acute myeloid leukemia is often treated using RA-based therapies that force immature white blood cells to mature, slowing their rapid growth. Retinoic acid works through complex signaling and gene regulation involving a group of proteins that orchestrate this transformation. In this study, the team used HL-60 cells, a model for human leukemia, and engineered them to express FGR. Surprisingly, the presence of FGR alone was enough to make these cells mature in a way almost identical to what happens with RA treatment. They began producing well-known markers of maturation such as CD38 and CD11b, generated reactive oxygen species (ROS), and expressed the inhibitor of the cell cycle, p27, all signs that the cells had shifted from a cancer-like, fast-dividing state to a more specialized, mature form. 

Further analysis revealed that FGR activated a group of proteins known as the "signalsome," which helps trigger the changes needed for cells to differentiate. This same group is typically activated by RA. 

“Notably, FGR induces the expression of genes targeted by RAR/RXR, such as cd38 and blr1, even without RA."

To test its potential use in treatment-resistant leukemias, the researchers introduced FGR into RA-resistant HL-60 cells. In these, FGR did not cause the same maturation process, which suggests that there are other problems with cell signaling that stop both the RA and FGR pathways. This result highlights the complexity of resistance mechanisms and the need for additional research.

These findings challenge the traditional view of FGR as strictly a cancer-driving protein. Instead, in this specific context, it appears to initiate anti-cancer behavior. That a single protein can reproduce the effects of a complex therapeutic compound like RA is both surprising and promising. If future research confirms this study's results in more advanced models, FGR could become a new tool for developing therapies for AML and potentially other blood cancers.

DOI - https://doi.org/10.18632/oncotarget.28705

Correspondence to - Andrew Yen - ay13@cornell.edu

Video short - https://www.youtube.com/watch?v=v2fjeFFoUPQ

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

About Oncotarget 

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh

MEDIA@IMPACTJOURNALS.COM

Single Protein Mimics Retinoic Acid Therapy to Help Leukemia Cells Mature

This song is a heartfelt tribute to early detection and the power of artificial intelligence and modern science. Inspired by the real-life stories of patients who discovered cancer at its earliest—and most treatable—stage, “I Took the Test (And I'm Still Here)” brings a message of hope, not fear.

As a physician, I’ve seen firsthand the difference it makes when cancer is found before symptoms ever appear. The Galleri® test is a multi-cancer early detection tool that can identify signals for dozens of cancers through a simple blood draw—many of which don’t have routine screening options.

This isn’t a song about worry. It’s about being proactive, about giving yourself and your loved ones more time, more options, and more life.

I hope this song opens up a conversation. Because sometimes the best way to treat cancer… is to catch it before it starts to shout.

Took the Test (And I'm Still Here)

I studion sitter Martin, Panos och Ludvig.
Det blir en MASTIG The Last of Us-special i veckans avsnitt. Vi spoilar precis allt som går att spoila och pratar om spel och TV-serie om vartannat. Var landar vi? Det får ni lyssna och se. Dessutom så bryter vi av med att både prata om filmen Dear John men också om saker som tagit slut och spelstudios som stängt ner. Dessutom smutskastar vi ett anonymt universitet av ingen särskild anledning. Spännande.

8:33 - Intro
11:12 - The Last of Us Part 2 och The Last of Us säsong 2
1:10:49 - Dear John
1:30:54 - Tre Snabba

Har DU något att säga till oss? Tips på något att prata om, åsikter om något vi sagt eller vill kanske bara säga hej? Skriv till oss på Facebook, följ oss på Instagram @medisradio och mejla till oss på medisradio@gmail.com. Vill ni se oss spela spel på Twitch så följ oss på @MedisRadioTV.

Musik: Pontus Ljung


193 - The Last of Us och Dear John

BUFFALO, NY - July 7, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on June 17, 2025, titled “Genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A single institution experience.”

In this study, a research team led by first author Fei Fei and corresponding author Michelle Afkhami from the City of Hope Comprehensive Cancer Center investigated a rare and aggressive type of blood cancer called blastic plasmacytoid dendritic cell neoplasm (BPDCN). Their research uncovered frequent mutations in key genes and identified CCDC50 as a potential biomarker for diagnosis and disease monitoring. These findings could help improve how this cancer is detected and treated in the future.

BPDCN most often affects older adults and is known for its rapid progression and poor survival rates. The researchers performed genetic sequencing on 21 patients to better understand the disease. They found that two genes, TET2 and ASXL1, were frequently mutated in these patients and were linked to worse survival, especially in those over 65 years old.

“Our study revealed that TET2 (57%) and ASXL1 (33%) were the most frequently mutated genes, followed by NRAS (29%), SRSF2 (14%), ZRSR2 (14%), and KMT2D (14%).”

The study also discovered that a gene called CCDC50 was expressed at much higher levels in BPDCN samples compared to other blood cancers, such as acute myeloid leukemia and chronic monomyelocytic leukemia. This suggests that CCDC50 may help clinicians distinguish BPDCN from other similar diseases. Importantly, CCDC50 levels dropped significantly in patients whose disease went into remission, highlighting its potential as a tool for tracking disease activity over time.

Researchers further observed that patients who received stem cell transplants lived longer than those who did not, reinforcing the importance of this treatment approach. However, BPDCN remains a challenging disease with an overall poor outlook, making these findings an important step toward better care.

This research provides new insights into the genetic changes behind BPDCN and points to CCDC50 as a promising marker to improve diagnosis and monitor treatment success. Larger studies will be needed to confirm these results and bring these discoveries closer to use in routine medical practice.

DOI - https://doi.org/10.18632/oncotarget.28742

Correspondence to - Michelle Afkhami - mafkhami@coh.org

Video short - https://www.youtube.com/watch?v=wUjr3uU3onI

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28742

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, Blastic plasmacytoid dendritic cell neoplasm (BPDCN), Next-generation sequencing (NGS), CCDC50

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh

MEDIA@IMPACTJOURNALS.COM

Key Genetic Alterations and Biomarker for Blastic Plasmacytoid Dendritic Cell Neoplasm

Visit: https://healthcheckbox.com/af/early-signs-of-leukemia-in-adults/
Hello everyone, my name is Oliver Smith, and I am here to talk about the early signs of leukemia in adults. Leukemia is a cancer that occurs in the bone marrow which resulting in an excessive amount of formation of white blood cells being formed in the body. This can be of many types, where one type is mostly seen in children and other types can be seen in adults. Early signs of leukemia can include persistent fatigue, frequent infections, unexplained weight loss, and swollen lymph nodes. This can be a serious problem if not treated on time. If you want to know more about this topic, just visit our site and learn more about the early signs of leukemia in adults.

Leukemia Red Flags | Early Signs of Leukemia in Adults

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare blood cancer that primarily affects older adults. One of the key challenges in diagnosing and treating BPDCN is that it closely resembles other forms of leukemia in both appearance and behavior. This overlap often leads to delays or uncertainty in diagnosis, especially since currently there is no single, reliable marker that clearly distinguishes BPDCN from related diseases.

To address this issue, researchers from the City of Hope Comprehensive Cancer Center investigated the genetic profile of BPDCN.  Their study, titled “Genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A single institution experience,” was published in Oncotarget (Volume 16).

Full blog - https://www.oncotarget.org/2025/10/22/genetic-study-identifies-potential-diagnostic-marker-for-rare-blood-cancer-bpdcn/

Paper DOI - https://doi.org/10.18632/oncotarget.28742

Correspondence to - Michelle Afkhami - mafkhami@coh.org

Abstract video - https://www.youtube.com/watch?v=wUjr3uU3onI

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28742

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, Blastic plasmacytoid dendritic cell neoplasm (BPDCN), Next-generation sequencing (NGS), CCDC50

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh

MEDIA@IMPACTJOURNALS.COM

Genetic Study Identifies Potential Diagnostic Marker for Rare Blood Cancer BPDCN

Hier verskaf ons gesondheidsorgdienste, opvoeding oor vroeë tekens van kolonkanker, die risiko daaraan verbonde en voorkomingswenke.

Patriot to the Core highlights selfless Americans.  I interview those from all branches of the military (combat controllers, PJs, Green Berets, SEALs, Rangers, Infantrymen, Marines, Pilots, etc) and the US government.  In addition, I speak with your every day mom who goes about doing good--from starting a non-profit to fighting for freedom in our communities and schools.  I get to talk with Gold Star Parents, Siblings and Spouses, and Medal of Honor recipients.  

This provides an opportunity to learn about everyday Americans who go above and beyond to protect us and to help others.  As a Gold Star brother, many of my guests have a military connection, but I still have a wide variety of people who answer the call to serve in various ways.  

We talk fighting terrorism, self protection, exercise, mental toughness, charity, parenting, fugitives and occasionally pop culture and politics.     

Please follow and subscribe so we can have many seasons to come.  Send suggestions and questions to me at thad@patriottothecore.com.  Hope you enjoy!

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.

Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/

A BLRB is your gateway to capturing attention and sparking interest in your latest music, TV, film, or literary project. Think of it as a dynamic, engaging promo that can be visual, audio, or video-based. We’ve got the audience—you need the eyes and ears! Let us bridge that gap and connect your project with the eager audience it deserves. Ready to make an impact? Join us and let’s get your project noticed!

BLRB. Supporting the arts, one BLRB at a time.

Welcome to the Real Quick w/ Mike Swick Podcast! Shot on location in Mike's custom studio in Phuket Thailand.

Business E-mail: Info@MikeSwick.com

Mike Swick is a 15-time UFC veteran and a former top contender in two different weight classes. He is also the founder and CEO of the AKA Thailand super gym in Phuket, as well as owner of MikeSwick.com, and also built one of northern California's largest print shops, Spartan Screen Printing. 

Mike Swick:
http://www.Instagram.com/Mike_Swick
http://www.twitter.com/OfficialSwick
http://www.Facebook.com/MikeSwick

Real Quick With Mike Swick Podcast:
https://www.youtube.com/c/RealQuickwMikeSwickPodcast
https://www.instagram.com/realquickwithmikeswick

Quick Swick Clips:
http://www.youtube.com/c/QuickSwickClips

AKA Thailand:
The World’s 1st Sports Combat Luxury Training Resort For Everyone! 
Muay Thai, MMA, BJJ, Fitness, AKA Airdyne, & Restaurant
*Trip Advisor 5 Star Rated* 
https://akathailand.com
https://www.instagram.com/akathailand
https://www.youtube.com/c/AKAThailandGym

Design Matters by Debbie Millman features interviews with designers, artists and cultural leaders, including Lawrence Weiner, Barbara Kruger, Malcolm Gladwell, Eric Kandel, Stefan Sagmeister, John Maeda, Jonathan Hoefler and Tobias Frere-Jones, Michael Arad, Milton Glaser, Massimo Vignelli, Paula Scher, Steven Heller, Jonah Lehrer, among others.

In 2011, Design Matters received the People’s Design Award from the prestigious Cooper-Hewitt National Design Awards.

Subscribe to Design Matters for free on iTunes, where new episodes are uploaded weekly: http://itunes.apple.com/us/podcast/design-matters-debbie-millman/id328074695

Medis Radio är Sveriges bästa podcast om popkultur. Den drivs av Martin Lindberg, Panos Tufexis, Ludvig Lundberg och Theo Tapper och behandlar alla typ av fin- och fulkultur. Recensioner och analyser av TV-serier, film, TV-spel, böcker och mycket mer blandas med tävlingar, besök av gäster och en inblick i redaktionens dagliga äventyr. Är du intresserad av media och popkultur? Då är Medis Radio den perfekta podcasten för dig. Nya avsnitt varje måndag klockan 18:00. Följ oss även på YouTube på kanalen Medis Radio TV, där lägger vi ut specialavsnitt och annat popkulturellt innehåll.

New tracks tagged #Leukemia